Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd.
By therapeutic area
Not enough TA-specific data (need ≥3 deals per TA).
By stage at signing
| Phase | Premium | Deals |
|---|---|---|
| phase 2 | ×0.70 | 3 |
Strategy profile
Based on 8 disclosed transactions, Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. concentrates its licensing activity in Oncology, Metabolic, and Neurology. Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. pays a 0.70x discount to market median. Their most common deal structure is License, with an average disclosed value of $134M. Most recent activity: 2019.
Pipeline coverage & gaps
Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. has disclosed activity in 0 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| LicensePrimary | 7 | $12M | $143M |
| Collaboration | 1 | $40M | $75M |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2019 | SurVaxM | MimiVax, LLC | glioblastoma | phase_2 | $10M | $148M |
| 2019 | CTX and hRPC cell-therapy programmes | ReNeuron Limited | post-stroke disability and retinitis pigmentosa | phase_2 | $8M | $130M |
| 2018 | RT002 | Revance Therapeutics, Inc. | glabellar lines | phase_3 | $30M | $261M |
| 2018 | tenapanor | Ardelyx | hyperphosphatemia, IBS-C | phase_3 | $12M | $125M |
| 2017 | tenapanor | Ardelyx, Inc. | irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperphosphatemia related to chronic kidney disease | phase_3 | $12M | $125M |
| 2017 | bremelanotide | Palatin Technologies, Inc. | hypoactive sexual desire disorder | phase_3 | $5M | $105M |
| 2017 | bremelanotide | Palatin Technologies, Inc. | hypoactive sexual desire disorder | phase_3 | $5M | $105M |
| 2017 | axicabtagene ciloleucel | Kite Pharma, Inc. | B-cell lymphomas and leukemias | phase_2 | $40M | $75M |
How this is computed
For each Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 3 disclosed deal premiums vs. peer medians. Raw premium 0.186, clamped to [0.7, 1.5].